Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxazosin mesylate
Drug ID BADD_D00719
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Marketing Status Prescription; Discontinued
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D00608
MeSH ID D017292
PubChem ID 62978
TTD Drug ID D03MIR
NDC Product Code 53869-2720; 59762-2320; 55111-005; 0049-2710; 53808-1107; 43353-646; 71610-120; 0832-1359; 71610-110; 0832-0357; 59762-2380; 71610-251; 43353-740; 0832-1358; 0049-2770; 0049-2720; 0093-2069; 50090-3143; 65427-012; 65427-016; 43353-739; 59762-2340; 0049-2760; 59762-2310; 0093-2068; 0832-0356; 0049-2750; 0093-2070; 53869-2780; 0093-2067; 0049-2780; 53869-2710; 53869-2740; 71610-482; 65862-204; 46014-1001; 53104-7521; 71610-420
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C24H29N5O8S
CAS Registry Number 77883-43-3
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysuria20.02.02.002--
Ear pain04.03.01.003--
Eczema23.03.04.006--
Epistaxis24.07.01.005; 22.04.03.001--
Eye pain06.08.03.002--
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.004--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastroenteritis07.19.03.001; 11.01.07.004--Not Available
Gout14.09.01.001; 15.01.06.001--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematuria24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hepatitis cholestatic09.01.01.002--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages